Stout Advises Healthmark Industries on Sale to Getinge AB

Stout announced today that its client, Healthmark Industries Company, Inc., has been acquired by Getinge AB for $320 million, representing a multiple of 17x estimated EBITDA for 2023. Getinge AB, founded in 1904 and based in Gothenburg, Sweden, is a leading global manufacturer of medical equipment and associated consumables used by hospitals for reprocessing and sterilization of surgical instruments and medical devices. It is also a leading manufacturer and marketer of equipment used in cardiac surgery, operating suites, and pharmaceutical production.

Founded in 1969 and based in Fraser, Michigan, Healthmark Industries is a leading manufacturer, marketer, and distributor of consumable medical devices and supplies used by sterile processing departments in hospitals for cleaning verification and sterile instrument packaging. In its fiscal year ending October 31, 2023, Healthmark expects revenue to increase 15% to $126 million.

Stout served as exclusive financial advisor to Healthmark in connection with this transaction.

Stout Managing Director John Calcagnini, who led the deal team, said, “The acquisition is expected to significantly enhance Getinge’s consumable offering to complement its sales of sterilization and reprocessing equipment, offering hospital customers a complete and best-in-class bundle of products and services designed to drive market share inroads.

“We also see an enormous opportunity for Getinge to expand distribution of Healthmark products to its’ international customers, as Healthmark generates 90% of revenue in the U.S. today. We don’t see why they could not grow the business to the point where international represents 50% of the mix, which is what we see with other large medical device manufacturers.”

Mark Basile, CEO of Healthmark, said, “We chose Stout for their expertise in medical devices and track record in managing cross-border transactions like ours, and that proved to be a great call. We would like to thank them for their leadership, efficiency, professionalism, knowledge, and excellent work in managing our process and putting together this important transaction. Stout’s assistance was irreplaceable, particularly in putting the finer points of the deal together and helping to map out the synergies. At the end of the day, Stout helped bring excellent value to the shareholders of Healthmark.”

Stout’s Eric Froidevaux, Max Halsted, Jake Kussin-Bordo, and Nate Lombard assisted in executing the deal.

Howard & Howard served as legal counsel to Healthmark. Covington and Burling LLP acted as legal counsel to Getinge AB.

SourceSTOUT

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”